Martin Clynes

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3876917/publications.pdf

Version: 2024-02-01

151 papers	5,487 citations	61945 43 h-index	98753 67 g-index
153 all docs	153 docs citations	153 times ranked	8497 citing authors

#	Article	IF	Citations
1	Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis, 2013, 34, 2300-2308.	1.3	359
2	Î±-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. Journal of Clinical Investigation, 2010, 120, 4236-4250.	3.9	264
3	In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies. Frontiers in Oncology, 2014, 4, 40.	1.3	205
4	A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy. Blood, 2014, 124, 999-1009.	0.6	138
5	Bone Disease in Multiple Myeloma: Pathophysiology and Management. Cancer Growth and Metastasis, 2014, 7, CGM.S16817.	3.5	131
6	Pre-exposure to yeast protects larvae of Galleria mellonella from a subsequent lethal infection by Candida albicans and is mediated by the increased expression of antimicrobial peptides. Microbes and Infection, 2006, 8, 2105-2112.	1.0	124
7	Conditioned media from cell lines: A complementary model to clinical specimens for the discovery of diseaseâ€specific biomarkers. Proteomics, 2011, 11, 794-804.	1.3	123
8	Comparison of 5 microplate colorimetric assays forin vitro cytotoxicity testing and cell proliferation assays. Cytotechnology, 1993, 11, 49-58.	0.7	120
9	Predicting cell-specific productivity from CHO gene expression. Journal of Biotechnology, 2011, 151, 159-165.	1.9	100
10	Induction of apoptosis in yeast and mammalian cells by exposure to 1,10-phenanthroline metal complexes. Toxicology in Vitro, 2004, 18, 63-70.	1.1	98
11	Proteomic approaches for serum biomarker discovery in cancer. Anticancer Research, 2007, 27, 1247-55.	0.5	95
12	Initial identification of low temperature and culture stage induction of miRNA expression in suspension CHO-K1 cells. Journal of Biotechnology, 2007, 130, 213-218.	1.9	90
13	Acid phosphatase: Endpoint for in vitro toxicity tests. In Vitro Cellular & Developmental Biology, 1991, 27, 183-184.	1.0	89
14	Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: A prognostic study. International Journal of Cancer, 2004, 112, 286-294.	2.3	89
15	Synthesis and X-ray crystal structure of [Ag(phendio)2]ClO4 (phendio = 1,10-phenanthroline-5,6-dione) and its effects on fungal and mammalian cells. BioMetals, 2004, 17, 635-645.	1.8	83
16	RNAi knockdown of Hop (Hsp70/Hsp90 organising protein) decreases invasion via MMP-2 down regulation. Cancer Letters, 2011, 306, 180-189.	3.2	82
17	Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-Glycoprotein. PLoS ONE, 2012, 7, e40717.	1.1	79
18	Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression. BMC Cancer, 2015, 15, 329.	1.1	77

#	Article	IF	Citations
19	Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. Journal of Translational Medicine, 2008, 6, 53.	1.8	73
20	Microarray and proteomics expression profiling identifies several candidates, including the valosinâ€containing protein (VCP), involved in regulating high cellular growth rate in production CHO cell lines. Biotechnology and Bioengineering, 2010, 106, 42-56.	1.7	72
21	2â€Ð difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins. Electrophoresis, 2007, 28, 4302-4310.	1.3	71
22	Identification of microRNAs with a role in glucose stimulated insulin secretion by expression profiling of MIN6 cells. Biochemical and Biophysical Research Communications, 2010, 396, 457-462.	1.0	68
23	Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Research and Treatment, 2008, 109, 359-365.	1.1	65
24	Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib. Clinical Cancer Research, 2009, 15, 7153-7160.	3.2	65
25	Lack of prognostic significance of survivin, survivin-Î”Ex3, survivin-2B, galectin-3, bag-1, bax-Î± and MRP-1 mRNAs in breast cancer. Cancer Letters, 2003, 201, 225-236.	3.2	63
26	Large scale microarray profiling and coexpression network analysis of CHO cells identifies transcriptional modules associated with growth and productivity. Journal of Biotechnology, 2011, 155, 350-359.	1.9	62
27	The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemotherapy and Pharmacology, 2013, 71, 1357-1368.	1.1	62
28	Analysis of acuteâ€phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. International Journal of Cancer, 2012, 131, 911-923.	2.3	61
29	Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 795-809.	1.5	60
30	Phenotypic and global gene expression profile changes between low passage and high passage MIN-6 cells. Journal of Endocrinology, 2006, 191, 665-676.	1.2	58
31	MiR-7 Triggers Cell Cycle Arrest at the G1/S Transition by Targeting Multiple Genes Including Skp2 and Psme3. PLoS ONE, 2013, 8, e65671.	1.1	57
32	Impact of miR-7 over-expression on the proteome of Chinese hamster ovary cells. Journal of Biotechnology, 2012, 160, 251-262.	1.9	56
33	Examining the Relationship between Cancer Invasion / Metastasis and Drug Resistance. Current Cancer Drug Targets, 2002, 2, 257-277.	0.8	55
34	Differential Expression of Fourteen Proteins between Uveal Melanoma from Patients Who Subsequently Developed Distant Metastases versus Those Who Did Not. , 2012, 53, 4634.		54
35	Drug resistance in cancer â€“ searching for mechanisms, markers and therapeutic agents. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 805-817.	1.5	51
36	Proteomic screening of glucose-responsive and glucose non-responsive MIN-6 beta cells reveals differential expression of proteins involved in protein folding, secretion and oxidative stress. Proteomics, 2006, 6, 6578-6587.	1.3	49

#	Article	IF	Citations
37	Proteomic profiling of CHO cells with enhanced rhBMPâ€2 productivity following coâ€expression of PACEsol. Proteomics, 2008, 8, 2611-2624.	1.3	49
38	MDR-1, but notMDR-3gene expression, is associated with unmutated IgVHgenes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2006, 47, 2308-2313.	0.6	48
39	Proteomic analysis of multidrugâ€resistance mechanisms in adriamycinâ€resistant variants of DLKP, a squamous lung cancer cell line. Proteomics, 2009, 9, 1556-1566.	1.3	48
40	Challenges of drug resistance in the management of pancreatic cancer. Expert Review of Anticancer Therapy, 2010, 10, 1647-1661.	1.1	47
41	Utilization and evaluation of CHOâ€specific sequence databases for mass spectrometry based proteomics. Biotechnology and Bioengineering, 2012, 109, 1386-1394.	1.7	46
42	Proteomic profiling of cardiomyopathic tissue from the aged mdx model of Duchenne muscular dystrophy reveals a drastic decrease in laminin, nidogen and annexin. Proteomics, 2013, 13, 2312-2323.	1.3	46
43	Biochemical relapse following radical prostatectomy and miRâ€200a levels in prostate cancer. Prostate, 2012, 72, 1193-1199.	1.2	45
44	CHO cell culture longevity and recombinant protein yield are enhanced by depletion of miRâ€7 activity via sponge decoy vectors. Biotechnology Journal, 2014, 9, 396-404.	1.8	45
45	Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro. Anticancer Research, 2002, 22, 3117-25.	0.5	45
46	Transcriptional Profiling of Gene Expression Changes in a PACE-Transfected CHO DUKX Cell Line Secreting High Levels of rhBMP-2. Molecular Biotechnology, 2008, 39, 187-199.	1.3	44
47	Synthesis of indomethacin analogues for evaluation as modulators of MRP activity. Bioorganic and Medicinal Chemistry, 2001, 9, 745-762.	1.4	42
48	Reâ€programming CHO cell metabolism using miRâ€23 tips the balance towards a highly productive phenotype. Biotechnology Journal, 2015, 10, 1029-1040.	1.8	42
49	The multidrug-resistant human lung tumour cell line, DLKP-A10, expresses novel drug accumulation and sequestration systems. Biochemical Pharmacology, 1997, 53, 1493-1502.	2.0	41
50	The use of reverse transcriptase-polymerase chain reaction (RT-PCR) to investigate specific gene expression in multidrug-resistant cells. Cytotechnology, 1993, 12, 289-314.	0.7	40
51	Development of a high-performance liquid chromatographicâ€“mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 3982-3990.	1.2	38
52	PP2A inhibition overcomes acquired resistance to HER2 targeted therapy. Molecular Cancer, 2014, 13, 157.	7.9	38
53	Cytogenetic comparison of two poorly differentiated human lung squamous cell carcinoma lines. Cancer Genetics and Cytogenetics, 1992, 59, 111-118.	1.0	35
54	Enhancedin vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. International Journal of Cancer, 2004, 111, 484-493.	2.3	35

#	Article	IF	Citations
55	Human Lung Carcinoma Cell Line DLKP Contains 3 Distinct Subpopulations with Different Growth and Attachment Properties. Tumor Biology, 1998, 19, 88-103.	0.8	34
56	A novel panel of protein biomarkers for predicting response to thalidomideâ€based therapy in newly diagnosed multiple myeloma patients. Proteomics, 2011, 11, 1391-1402.	1.3	33
57	Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines. Anticancer Research, 2007, 27, 1361-4.	0.5	33
58	Altered expression of mRNAs for apoptosis-modulating proteins in a low level multidrug resistant variant of a human lung carcinoma cell line that also expressesmdr1 mRNA. , 1999, 82, 368-376.		32
59	Rapid and sensitive liquid chromatographyâ€“tandem mass spectrometry for the quantitation of epirubicin and identification of metabolites in biological samples. Talanta, 2007, 72, 145-154.	2.9	32
60	Proteomic differences in recombinant CHO cells producing two similar antibody fragments. Biotechnology and Bioengineering, 2016, 113, 1902-1912.	1.7	29
61	Processâ€relevant concentrations of the leachable b<scp>D</scp>t<scp>BPP</scp> impact negatively on C<scp>HO</scp> cell production characteristics. Biotechnology Progress, 2016, 32, 1547-1558.	1.3	29
62	Filter-Aided Sample Preparation (FASP) for Improved Proteome Analysis of Recombinant Chinese Hamster Ovary Cells. Methods in Molecular Biology, 2017, 1603, 187-194.	0.4	29
63	Identification and Functional Validation of RAD23B as a Potential Protein in Human Breast Cancer Progression. Journal of Proteome Research, 2014, 13, 3212-3222.	1.8	28
64	Elevated levels of 14-3-3 proteins, serotonin, gamma enolase and pyruvate kinase identified in clinical samples from patients diagnosed with colorectal cancer. Clinica Chimica Acta, 2015, 441, 133-141.	0.5	28
65	Neutrophil Membrane Cholesterol Content is a Key Factor in Cystic Fibrosis Lung Disease. EBioMedicine, 2017, 23, 173-184.	2.7	28
66	Continuous translation of circularized mRNA improves recombinant protein titer. Metabolic Engineering, 2019, 52, 284-292.	3.6	28
67	Isolation from a human MDR lung cell line of multiple clonal subpopulations which exhibit significantly different drug resistance. , 1997, 71, 907-915.		27
68	Transcriptomic analysis of clonal growth rate variation during CHO cell line development. Journal of Biotechnology, 2013, 166, 105-113.	1.9	26
69	Decreasing Txnip mRNA and Protein Levels in Pancreatic MIN6 Cells Reduces Reactive Oxygen Species and Restores Glucose Regulated Insulin Secretion. Cellular Physiology and Biochemistry, 2010, 25, 667-674.	1.1	25
70	Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry. BBA Clinical, 2017, 7, 97-104.	4.1	25
71	The iron-responsive microsomal proteome of Aspergillus fumigatus. Journal of Proteomics, 2016, 136, 99-111.	1.2	24
72	A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer. British Journal of Cancer, 2017, 117, 1326-1335.	2.9	24

#	Article	IF	Citations
73	Glycosylation patterns of kidney proteins differ in rat diabetic nephropathy. Kidney International, 2015, 87, 963-974.	2.6	23
74	Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Research, 2004, 24, 457-64.	0.5	23
75	Ultra-deep next generation mitochondrial genome sequencing reveals widespread heteroplasmy in Chinese hamster ovary cells. Metabolic Engineering, 2017, 41, 11-22.	3.6	22
76	Reinventing the Wheel: Synthetic Circular RNAs for Mammalian Cell Engineering. Trends in Biotechnology, 2020, 38, 217-230.	4.9	22
77	A Comparative Quantitative LC-MS/MS Profiling Analysis of Human Pancreatic Adenocarcinoma, Adjacent-Normal Tissue, and Patient-Derived Tumour Xenografts. Proteomes, 2018, 6, 45.	1.7	21
78	Interaction of Plasma Deposited HMDSO-Based Coatings with Fibrinogen and Human Blood Plasma: The Correlation between Bulk Plasma, Surface Characteristics and Biomolecule Interaction. Plasma Processes and Polymers, 2010, 7, 411-421.	1.6	20
79	The Expression Pattern of the Phosphoproteome Is Significantly Changed During the Growth Phases of Recombinant CHO Cell Culture. Biotechnology Journal, 2018, 13, e1700221.	1.8	20
80	Recent advances in clinical proteomics using mass spectrometry. Bioanalysis, 2010, 2, 1609-1615.	0.6	19
81	Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients. BBA Clinical, 2017, 8, 28-34.	4.1	19
82	Leaky Expression of the TET-On System Hinders Control of Endogenous miRNA Abundance. Biotechnology Journal, 2019, 14, 1800219.	1.8	19
83	Development and characterization of a Chinese hamster ovary cell-specific oligonucleotide microarray. Biotechnology Letters, 2011, 33, 1773-1779.	1.1	18
84	Transferrin-bound proteins as potential biomarkers for advanced breast cancer patients. BBA Clinical, 2014, 2, 24-30.	4.1	18
85	Proteomics in uveal melanoma. Experimental Eye Research, 2014, 118, 1-12.	1.2	18
86	DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models. Journal of Controlled Release, 2020, 324, 610-619.	4.8	18
87	Imatinib and docetaxel in combination can effectively inhibit glioma invasion in an in vitro 3D invasion assay. Journal of Neuro-Oncology, 2011, 101, 189-198.	1.4	17
88	Metabolomic and proteomic analysis of breast cancer patient samples suggests that glutamate and 12-HETE in combination with CA15-3 may be useful biomarkers reflecting tumour burden. Metabolomics, 2015, 11, 620-635.	1.4	17
89	Differential Phosphoproteomic Analysis of Recombinant Chinese Hamster Ovary Cells Following Temperature Shift. Journal of Proteome Research, 2017, 16, 2339-2358.	1.8	17
90	Polypyridylâ€Based Copper Phenanthrene Complexes: Combining Stability with Enhanced DNA Recognition. Chemistry - A European Journal, 2021, 27, 971-983.	1.7	17

#	Article	IF	Citations
91	Exposure of a Corneal Epithelial Cell Line (hTCEpi) to Demodex-Associated Bacillus Proteins Results in an Inflammatory Response. Investigative Ophthalmology and Visual Science, 2014, 55, 7019-7028.	3.3	16
92	Towards next generation CHO cell biology: Bioinformatics methods for RNAâ€Seqâ€based expression profiling. Biotechnology Journal, 2015, 10, 950-966.	1.8	16
93	Parallel mRNA, proteomics and miRNA expression analysis in cell line models of the intestine. World Journal of Gastroenterology, 2017, 23, 7369-7386.	1.4	16
94	Recent developments in drug resistance and apoptosis research. Critical Reviews in Oncology/Hematology, 1998, 28, 181-205.	2.0	15
95	2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines. Journal of Proteomics, 2011, 74, 490-501.	1.2	15
96	Copper-induced non-monotonic dose response in Caco-2 cells. In Vitro Cellular and Developmental Biology - Animal, 2019, 55, 221-225.	0.7	15
97	Microarray expression profiling identifies genes regulating sustained cell specific productivity (Sâ€Qp) in CHO K1 production cell lines. Biotechnology Journal, 2012, 7, 516-526.	1.8	14
98	Unexpected fluctuations of trace element levels in cell culture medium in vitro: caveat emptor. In Vitro Cellular and Developmental Biology - Animal, 2018, 54, 555-558.	0.7	14
99	The emerging role of cellular post-translational modifications in modulating growth and productivity of recombinant Chinese hamster ovary cells. Biotechnology Advances, 2021, 49, 107757.	6.0	14
100	CGCDB: A web-based resource for the investigation of gene coexpression in CHO cell culture. Biotechnology and Bioengineering, 2012, 109, 1368-1370.	1.7	13
101	Quantitative label-free mass spectrometry analysis of formalin-fixed, paraffin-embedded tissue representing the invasive cutaneous malignant melanoma proteome. Oncology Letters, 2016, 12, 3296-3304.	0.8	13
102	Transcriptomic analysis of IgG4 Fcâ€fusion protein degradation in a panel of clonallyâ€derived CHO cell lines using RNASeq. Biotechnology and Bioengineering, 2019, 116, 1556-1562.	1.7	13
103	Intricate effects of primary motor neuronopathy on contractile proteins and metabolic muscle enzymes as revealed by label-free mass spectrometry. Bioscience Reports, 2014, 34, .	1.1	12
104	Depletion of endogenous miRNA-378-3p increases peak cell density of CHO DP12 cells and is correlated with elevated levels of ubiquitin carboxyl-terminal hydrolase 14. Journal of Biotechnology, 2018, 288, 30-40.	1.9	12
105	Increased growth rate and productivity following stable depletion of miR-7 in a mAb producing CHO cell line causes an increase in proteins associated with the Akt pathway and ribosome biogenesis. Journal of Proteomics, 2019, 195, 23-32.	1.2	12
106	Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients. International Journal of Molecular Sciences, 2020, 21, 962.	1.8	12
107	Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib. Experimental Cell Research, 2012, 318, 641-652.	1.2	11
108	Clinical utility of Câ€terminal telopeptide of type 1 collagen in multiple myeloma. British Journal of Haematology, 2016, 173, 82-88.	1.2	10

#	Article	IF	Citations
109	Clonal variation in productivity and proteolytic clipping of an Fc-fusion protein in CHO cells: Proteomic analysis suggests a role for defective protein folding and the UPR. Journal of Biotechnology, 2018, 281, 21-30.	1.9	10
110	An arginase-based system for selection of transfected CHO cells without the use of toxic chemicals. Journal of Biological Chemistry, 2019, 294, 18756-18768.	1.6	9
111	Improvements in singleâ€use bioreactor film material composition leads to robust and reliable Chinese hamster ovary cell performance. Biotechnology Progress, 2019, 35, e2824.	1.3	9
112	Conditional Knockdown of Endogenous MicroRNAs in CHO Cells Using TET-ON-SanDI Sponge Vectors. Methods in Molecular Biology, 2017, 1603, 87-100.	0.4	8
113	Predictive biomarkers for dasatinib treatment in melanoma. Oncoscience, 2014, 1, 158-166.	0.9	8
114	Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact. Expert Review of Proteomics, 2016, 13, 383-394.	1.3	7
115	miRâ€CATCH Identifies Biologically Active miRNA Regulators of the Proâ€Survival Gene XIAP, in Chinese Hamster Ovary Cells. Biotechnology Journal, 2018, 13, e1700299.	1.8	7
116	Zinc supplementation increases protein titer of recombinant CHO cells. Cytotechnology, 2019, 71, 915-924.	0.7	7
117	Improved yield of rhEPO in CHO cells with synthetic 5â€² UTR. Biotechnology Letters, 2019, 41, 231-239.	1.1	7
118	The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias.. Blood, 2009, 114, 1729-1729.	0.6	7
119	Why we need good mentoring. Nature Reviews Cancer, 2019, 19, 489-493.	12.8	6
120	Proteomic Analysis of Cell Lines and Primary Tumors in Pancreatic Cancer Identifies Proteins Expressed Only In Vitro and Only In Vivo. Pancreas, 2020, 49, 1109-1116.	0.5	6
121	Subphysiological temperature induces pervasive alternative splicing in Chinese hamster ovary cells. Biotechnology and Bioengineering, 2020, 117, 2489-2503.	1.7	6
122	Statistical methods for mining Chinese hamster ovary cell â€˜omics data: from differential expression to integrated multilevel analysis of the biological system. Pharmaceutical Bioprocessing, 2014, 2, 469-481.	0.8	5
123	Proteomic analysis of pancreatic ductal adenocarcinoma. Expert Review of Proteomics, 2020, 17, 453-467.	1.3	5
124	Copper toxicity of inflection point in human intestinal cell line Caco-2 dissected: influence of temporal expression patterns. In Vitro Cellular and Developmental Biology - Animal, 2021, 57, 359-371.	0.7	5
125	Genomic Profiling and Functional Analysis of let-7c miRNA-mRNA Interactions Identify SOX13 to Be Involved in Invasion and Progression of Pancreatic Cancer. Journal of Oncology, 2020, 2020, 1-11.	0.6	5
126	Comparative Transcriptomic Analysis of Cultivated Limbal Epithelium and Donor Corneal Tissue Reveals Altered Wound Healing Gene Expression. , 2014, 55, 5795.		4

#	Article	IF	Citations
127	Phosphopeptide Enrichment and LC-MS/MS Analysis to Study the Phosphoproteome of Recombinant Chinese Hamster Ovary Cells. Methods in Molecular Biology, 2017, 1603, 195-208.	0.4	4
128	A proteomic profiling dataset of recombinant Chinese hamster ovary cells showing enhanced cellular growth following miR-378 depletion. Data in Brief, 2018, 21, 2679-2688.	0.5	4
129	Transfection of miR-31* boosts oxidative phosphorylation metabolism in the mitochondria and enhances recombinant protein production in Chinese hamster ovary cells. Journal of Biotechnology, 2021, 333, 86-96.	1.9	4
130	Mapping the molecular basis for growth related phenotypes in industrial producer CHO cell lines using differential proteomic analysis. BMC Biotechnology, 2021, 21, 43.	1.7	4
131	Engineering CHO cell growth by stable manipulation of miRNA expression. BMC Proceedings, 2011, 5, P22.	1.8	3
132	Differential expression of miRNAs and functional role of mir-200a in high and low productivity CHO cells expressing an Fc fusion protein. Biotechnology Letters, 2021, 43, 1551-1563.	1.1	3
133	Pharmacological interactions of TKIs with the P-gp drug transport protein.. Journal of Clinical Oncology, 2012, 30, 2536-2536.	0.8	3
134	Detection of Specific mRNAs in Culture Medium Conditioned by Human Tumour Cells: Potential for New Class of Cancer Biomarkers in Serum. Cancer Genomics and Proteomics, 2005, 2, 43-52.	1.0	3
135	Challenges in molecular analysis for individualized cancer therapy. Drug Discovery Today, 2003, 8, 531.	3.2	2
136	Development of whole-cell and cell-free biosensors for the detection and differentiation of organic and inorganic forms of copper. Metallomics, 2020, 12, 1729-1734.	1.0	2
137	Altered gene expression in CHO cells following polyamine starvation. Biotechnology Letters, 2020, 42, 927-936.	1.1	2
138	Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma. Blood, 2013, 122, 1869-1869.	0.6	2
139	Gene expression profiling of copper-resistant Caco-2 clones. Metallomics, 2020, 12, 1521-1529.	1.0	1
140	Characterisation and proteomic profiling of continuously exposed Cu-resistant variants of the Caco-2 cell line. Toxicology in Vitro, 2020, 65, 104773.	1.1	1
141	A gene expression profile indicative of early stage HER2 tyrosine kinase inhibitor response.. Journal of Clinical Oncology, 2013, 31, e11536-e11536.	0.8	1
142	Investigation and circumvention of transfection inhibition by ferric ammonium citrate in serumâ€free media for Chinese hamster ovary cells. Biotechnology Progress, 2020, 36, e2954.	1.3	0
143	LC-MS proteomic profiling of Caco-2 human intestinal cells exposed to the copper-chelating agent, triethylenetetramine: A preliminary study. Biochemical and Biophysical Research Communications, 2020, 524, 847-852.	1.0	0
144	Prediction of Thalidomide Response in the Newly Diagnosed Untreated Multiple Myeloma Patients Based on a Panel of Protein Biomarkers. Blood, 2008, 112, 5018-5018.	0.6	0

#	Article	IF	Citations
145	Proteomics as a Functional Tool in Evaluating Bortezomib Treatment and Drug Resistance Mechanism.. Blood, 2009, 114, 1805-1805.	0.6	0
146	Proteomic Characterization of An Isogenic Multiple Myeloma Cell Line Model of Bortezomib Resistance. Blood, 2011, 118, 1820-1820.	0.6	0
147	Prostate cancer inhibitory activity of a novel dual inhibitor, EL102, in combination with docetaxel, and its effects on MDR1-mediated drug resistance in vitro.. Journal of Clinical Oncology, 2012, 30, e15126-e15126.	0.8	0
148	Cells of the Osteoblast Lineage Confer Myeloma Cell Resistance to Established and Investigational Therapeutic Agents. Blood, 2012, 120, 3995-3995.	0.6	0
149	Examining the Impact of Altered Protein Expression and Ubiquitination Levels on the Development of Resistance to Proteasome Inhibitors Using Proteomics Analysis. Blood, 2015, 126, 4208-4208.	0.6	0
150	RNA Interference with siRNA. Cancer Genomics and Proteomics, 2006, 3, 127-135.	1.0	0
151	Gene Expression Microarray Technology: Some Applications in Lung Cancer Research. Cancer Genomics and Proteomics, 2006, 3, 197-202.	1.0	0